In vitro and in vivo effect of verapamil on human airway responsiveness to leukotriene D₄

JA ROBERTS, MA GIEMBYCZ, D RAEBURN, IW RODGER, NC THOMSON

From the Department of Respiratory Medicine, Western Infirmary, and the Department of Physiology and Pharmacology, University of Strathclyde, Glasgow

ABSTRACT The mechanism by which leukotriene D₄ (LTD₄) induces airway narrowing in man is unclear. We have investigated this by examining the effect of the calcium channel blocker verapamil on the sensitivity of in vitro preparations of human bronchi to LTD₄ and methacholine, and on the bronchoconstriction induced in normal subjects by these agonists in vivo. In vitro smooth muscle sensitivity was assessed by the concentration of LTD₄ and methacholine causing a 50% of maximum contraction (EC₅₀) and as the maximum tension generated. Verapamil did not alter baseline tension or the response to LTD₄ but did inhibit contractile responses to methacholine. In vivo studies were performed in six normal subjects; they inhaled increasing concentrations of LTD₄ (0.4-50 µg/ml) or methacholine (2-64 mg/ml). Airway responsiveness in vivo was expressed as the provocation concentration (PC) of agonist producing a 35% fall in specific airways conductance (PC₃₅sGaw) and a 30% fall in flow at 30% of vital capacity (PC₃₀V₃₀). Verapamil did not alter baseline sGaw or V₃₀. One subject did not respond to LTD₄ on either day. In contrast to the in vitro results, verapamil produced a greater than 10 fold reduction in LTD₄ induced bronchoconstriction, but had no effect on methacholine induced bronchoconstriction. These results suggest that in normal subjects bronchoconstriction induced by inhaled LTD₄ is due to a combination of direct and indirect mechanisms.

Leukotriene D₄ (LTD₄) is a potent bronchoconstrictor in man and may be an important mediator in asthma. Specific binding sites (receptors) for leukotrienes have been identified in the lungs of different species, including man. Although in vitro contractile responses of airway smooth muscle from these species have been shown to be receptor mediated, the mechanism or mechanisms underlying leukotriene induced bronchoconstriction in man in vivo is uncertain. Since contraction of airway smooth muscle is dependent on calcium ion influx, we have examined the effects of the calcium channel blocking drug verapamil on the airway response to inhaled LTD₄ in a group of normal subjects. We also examined the effects of verapamil on the in vitro LTD₄ concentration-response curve for human bronchial smooth muscle.

Methods

In Vitro Study

Bronchial tissue was obtained rapidly from lung removed from patients undergoing lung resection for bronchial carcinoma. Samples from second to sixth order bronchi were dissected from areas of macroscopically normal tissue and maintained at 4°C overnight in oxygenated Krebs-Henseleit physiological salt solution of the following composition: NaCl 118; KCl 4.7; MgSO₄ 1.2; KH₂PO₄ 1.2; CaCl₂ 2.5; NaHCO₃ 25; and glucose 11.7 mmol/l. On the following day bronchi were dissected free of extraneous connective tissue and sectioned to produce transverse strips of tissue. These were suspended, under a resting tension of 1.5 to 2.0 g, in a 5 ml organ bath containing Krebs-Henseleit solution at 37°C bubbled with 5% carbon dioxide in oxygen. During a 60 minute equilibration period the tissues were washed three times. Changes in isometric tension were measured with force-displacement transducers (Grass, FTO3C) and recorded on an ink writing polygraph (Grass, model 7).

The reproducibility of the contractile changes of the bronchial strips was assessed by adding methacholine (1 x 10⁻⁴ mol/l) on two occasions with an interval of 30 minutes for recovery after each drug had been added. A cumulative concentration-effect curve for LTD₄ or methacholine was then constructed by adding increasing concentrations of the drug,
Effect of verapamil on baseline lung function

<table>
<thead>
<tr>
<th>Leukotriene D₄ (n = 5)</th>
<th>Methacholine (n = 6)</th>
</tr>
</thead>
<tbody>
<tr>
<td>sGaw (s⁻¹ kPa⁻¹)</td>
<td>sGaw (s⁻¹ kPa⁻¹)</td>
</tr>
<tr>
<td>V₃₀(p) (l/s⁻¹)</td>
<td>V₃₀(p) (l/s⁻¹)</td>
</tr>
<tr>
<td><strong>Baseline</strong></td>
<td><strong>After treatment</strong></td>
</tr>
<tr>
<td>Verapamil</td>
<td>1.59 (0.17)</td>
</tr>
<tr>
<td>Control</td>
<td>1.88 (0.29)</td>
</tr>
<tr>
<td><strong>p value</strong></td>
<td>NS</td>
</tr>
</tbody>
</table>

sGaw—specific airways conductance.
V₃₀(p)—partial expiratory flow rate measured at 30% of vital capacity.

In each addition of the drug being made at the peak of the response produced by the preceding concentration. After washout of the agonist and full recovery to control resting tension, either verapamil (1 x 10⁻⁶ mol/l) or vehicle was added to the bath. Thirty minutes later a second concentration-effect curve was constructed. The concentration of LTD₄ and methacholine that produced a 50% (EC₅₀) of maximum contraction was calculated from the graphically displayed data. In each experiment four to six bronchial strips from each patient were examined. For each bronchial strip the responses to LTD₄ and methacholine elicited in the presence of verapamil were calculated as a percentage of that produced in the absence of the calcium channel blocking drug.

**IN VIVO STUDY**

We studied six normal subjects aged 22–36 years, five of them male. All were non-smokers and gave no history of respiratory disease and none was taking any drug treatment. The mean forced expiratory volume in one second (FEV₁), was 97.5% (SE 2.2%) of the predicted value. All subjects gave informed consent and the experimental protocol was approved by the Western significance ethical committee.

Airways resistance (Raw) and thoracic gas volume (TGV) were measured in a constant volume body plethysmograph (Fenyes and Gut, and we used a computerised data collection and analysis system based on the method of DuBois et al.⁹ The results were expressed as specific airways conductance (sGaw)

\[
\text{sGaw} = \frac{1}{\text{Raw} \times \frac{1}{\text{TGV}}}
\]

The mean of eight values measured was taken as sGaw. Flow-volume curves were constructed as follows. After a period of normal tidal breathing, the subject expired maximally from end tidal inspiratory volume to residual volume (RV) to obtain the partial expiratory flow-volume (PEFV) curve. When RV was reached, the subject inspired to total lung capacity (TLC) and then expired maximally to RV. From this manoeuvre FEV₁ and maximum expiratory flow at 70% of expired vital capacity, obtained from the partial flow-volume (V₃₀(p)) curve, were measured automatically (Collingwood Measurement). Measurements in the body plethysmograph measurements always preceded flow-volume recordings. Aerosols were generated with a Wright nebuliser by air at 50 lb/in² (345 kPa) at a flow rate of 8 l min⁻¹ to achieve an output of 0.15 ml min⁻¹.

Each subject received either inhaled verapamil (2.5 mg/ml) or normal saline in a randomised single blind manner on four separate days. After baseline measurements of sGaw (mean of eight readings) and V₃₀(p) (mean of five readings) the solutions were inhaled for five minutes. After 15 minutes lung function tests were repeated. Leukotriene D₄ and methacholine inhalation tests were carried out with a modification of our previously described method.⁹ The buffered saline was inhaled first, followed by increasing concentrations of LTD₄ (0.4–50 μg/ml) or methacholine (2–64 mg/ml). Each concentration was inhaled for two minutes. Inhalations were repeated every 15 minutes for LTD₄ and every 10 minutes for methacholine. Two LTD₄ and two methacholine inhalation tests were performed on each subject after verapamil and saline respectively. Results were expressed as the provocation concentration (PC) producing a 35% fall in sGaw (PC₅₅ sGaw) and a 30% fall in V₃₀(p). Results were compared by analysis of variance and Student’s t test.

**Results**

**IN VITRO STUDY**

LTD₄ (1 x 10⁻¹⁰ to 2 x 10⁻⁷) and methacholine (1 x 10⁻⁹ to 1 x 10⁻³) mol l⁻¹ elicited concentration dependent contractions of the bronchial strip preparations (fig 1). There was no significant difference in the sensitivities to LTD₄ or methacholine of bronchial strips prepared from the same patient. Mean (SE) EC₅₀ values from all experiments were 2.6 (0.8) x 10⁻⁸ mol/l (n = 7) for LTD₄ and 1.7 (0.3) x 10⁻⁶ mol/l (n = 18) for methacholine. Contractions to LTD₄ were slow to develop, taking 12 (4) minutes to achieve peak effect from each concentration of drug used. The mean maximum contraction elicited by LTD₄ at the highest concentration tested was 17 (3)
mN, though it was not normally possible to test concentrations in excess of $2 \times 10^{-7}$ mol/l because of the limited supply of the eicosanoid. This was not significantly different from the maximum contraction produced by methacholine (18 (2) mN). On the two occasions when LTD4 could be tested at a higher concentration ($4 \times 10^{-7}$ mol/l) the resulting contraction was no greater than that elicited by $2 \times 10^{-7}$ mol/l.

LTD4 induced contractions were slowly reversed, requiring 60–80 minutes to return to baseline tension levels with repeated washing of the tissue with fresh physiological salt solution. In a few experiments a second cumulative concentration-effect curve for LTD4 was constructed after an interval of about 120 minutes. There were no significant differences between the two curves—indeed, they could be virtually superimposed on each other.

Verapamil ($1 \times 10^{-6}$ mol/l) had no effect on baseline tension during the 30 minutes equilibration period. It was without significant effect on the major portion of the LTD4 concentration-effect curve, although a slight inhibition of response was observed at the highest concentration of LTD4 used (fig 1a).

The same concentration of verapamil inhibited all contractile responses to methacholine and depressed the maximum contraction by 29% (5%) (fig 1b).

**IN VIVO STUDY**

Inhalation of verapamil did not alter baseline sGaw or $V_{30}(p)$ (table). One subject failed to respond to LTD4 on either day. In the other five subjects verapamil significantly inhibited LTD4 induced bronchoconstriction (fig 2a). The geometric mean PC values underestimate the effect of verapamil on LTD4 induced bronchoconstriction since three subjects did not develop bronchoconstriction in response to the highest concentration of LTD4 administered. These subjects were assigned the highest concentration of LTD4 (50 μg/ml) as their PC value to allow statistical analysis. $PC_{35}$ sGaw LTD4 increased from 1.64 (0.62) μg/ml (geometric mean (SE)) after placebo to 20.11 (1.11) μg/ml after verapamil ($p < 0.01$). $PC_{30} V_{30}(p)$ LTD4 increased from 1.87 (3.17) μg/ml after placebo to 20.46 (1.57) μg/ml after verapamil ($p < 0.01$). All six subjects developed chest tightness but none coughed after LTD4.

Verapamil had no effect on responsiveness to methacholine (fig 2b). $PC_{35}$ sGaw methacholine was 8.67 (2.78) μg/ml after placebo and 6.81 (3.6) μg/ml after verapamil (not significant). $PC_{30} V_{30}(p)$ methacholine was 6.98 (3.60) mg/ml after placebo and 6.77 (1.59) mg/ml after verapamil (not significant).

**Discussion**

Inhaled verapamil inhibited LTD4 but not methacholine induced bronchoconstriction in normal subjects. In contrast, verapamil had no inhibitory effect on the response of human airway smooth muscle strips to LTD4 and only a small, though significant, inhibitory effect on the response to methacholine.

LTD4 and methacholine elicited concentration dependent contraction of isolated bronchial smooth muscle. In the case of methacholine these effects were clearly mediated via stimulation of muscarinic receptors since the responses were competitively inhibited.

**Figure 1** Effects of verapamil ($1 \times 10^{-6}$ mol/l) on (a) leukotriene D4 (LTD4) and (b) methacholine (MCh) induced contractions of human isolated bronchial preparations. Each point represents the mean (as percentage of control) maximum response from seven (panel a) and 18 (panel b) separate experiments before (●) and after (■) verapamil. Standard errors of the mean are shown by vertical bars.
by atropine (unpublished observations). In the absence of a suitable selective antagonist competing for LTD₄ receptors a similar experiment was not feasible with LTD₄. As in a previous study, however, contractions elicited by LTD₄ were unaffected by mepyramine or atropine or by inhibition of the cyclooxygenase pathway with flurbiprofen (unpublished observations), in keeping with a previous report.¹¹ These results would tend to exclude an indirect effect of LTD₄ mediated via histamine released from mast cells, acetylcholine released from vagal nerve terminals, constrictor cyclooxygenase products such as thromboxane A₂ or the constrictor prostaglandins PGF₂α and PGD₂. Thus the observed effects of LTD₄ in vitro are likely to be receptor mediated.

The in vitro studies were performed on tissue from patients who were older than the subjects tested in vivo, so an effect of age cannot be excluded. The preoperative and perioperative drugs received by the surgical patients are unlikely to have influenced in vitro responsiveness since all tissues were washed on several occasions and stored overnight in physiological saline before testing.⁹¹⁰

Contraction of airway smooth muscle is dependent on an increase in the concentration of calcium ions (Ca²⁺) within the myoplasm of the cell.⁶⁷¹² These so-called activator calcium ions may be supplied from the extracellular fluid surrounding the cell or from storage sites such as the sarcoplasmic reticulum, within the cell.⁶⁷¹² Contraction of guinea pig airway smooth muscle by agonists is highly resistant to inhibition with calcium channel blocking drugs such as verapamil and nifedipine.¹³¹⁴ There are few reports of calcium channel blocking drugs on contraction of human airway smooth muscle in vitro. The results of our study with verapamil are in agreement with those of previous studies, in which high concentrations (10⁻⁶ mol/l) of nifedipine and gallopamil (D600) were required to produce relatively small inhibition of contractions.¹¹¹⁵ This is consistent with the hypothesis that LTD₄ may rely principally in human airway smooth muscle, as it appears to in the guinea pig airway,¹³ on an intracellular source of activator Ca²⁺ to initiate contraction. In contrast, the inhibitory effect of verapamil on methacholine induced contractions in vitro suggests that a proportion of the contractile response to this agonist in human airway smooth muscle is dependent on influx of extracellular Ca²⁺ via calcium channels that are sensitive to inhibition by verapamil.

In contrast to our in vitro findings, in vivo verapamil significantly inhibited the bronchoconstriction induced by LTD₄ though not by methacholine. The striking difference between the effects of verapamil on LTD₄ induced bronchoconstriction in vivo and in vitro and the selectivity of its effect on LTD₄ in vivo

---

Fig 2  Effect of pretreatment with verapamil (2.5 mg/ml) or control (buffered saline) inhalations on airway responsiveness to (a) leukotriene (LTD₄) and (b) methacholine (MCh). Results are expressed as the provocation concentration (PC) producing a decrease in sGaw of 35% (PC₃₅sGaw) and a decrease in V₃₀(p) of 30% (PC₃₀V₃₀(p)). Verapamil significantly reduced the response to LTD₄ (p < 0.01) but not to methacholine.
suggests that verapamil is not acting solely on airway smooth muscle cells. Thus the airway response to LTD₄ in man may be mediated both by a direct effect on airway smooth muscle and indirectly via a verapamil sensitive pathway.

There are several potential pathways by which LTD₄ might indirectly cause bronchoconstriction. If LTD₄ is capable of stimulating sensory nerve endings in the airway this could result in reflex vagal bronchoconstriction. In dogs with hyperreactive airways and in guinea pigs pretreatment with atropine prevents LTD₄ induced bronchoconstriction. However, found that LTD₄ had no effect on sensory irritant receptors in cats and dogs, although in cats it potentiated the response to serotonin by a vagal dependent mechanism. Thus the role of vagal pathways in the response to LTD₄ in animals is unclear and in man untested. Furthermore, although neurotransmitter release is dependent on influx of extracellular Ca²⁺, this process is insensitive to inhibition by calcium channel blocking drugs.

The slow onset of bronchoconstriction with LTD₄ is consistent with release of secondary mediators as the mechanism of response. In guinea pigs intravenously administered leukotriene produces a reduction in dynamic compliance after pretreatment with a cyclo-oxygenase inhibitor, suggesting that some of the bronchoconstriction may be due to a generation of thromboxane A₂. However, found that pretreatment with oral aspirin failed to attenuate the response to LTD₄ in man.

LTD₄ may increase airway permeability, and, since epithelial transport mechanisms require calcium, these could be susceptible to a blocking action of verapamil. Verapamil might reduce LTD₄ induced changes in airway permeability and so affect access of LTD₄ to smooth muscle receptors and reduce the effect of LTD₄ in vivo.

In summary, our results suggest that in normal subjects LTD₄ induced bronchoconstriction may result from a combination of direct and indirect mechanisms. The pathway mediating the indirect effect of LTD₄ is at present unknown. Whether in asthmatic patients LTD₄ acts by similar mechanisms requires to be established.

References